Morepen Laboratories Clears ₹99 Cr Kotak Credit Facility, Assets to Be Released

Morepen Laboratories has fully repaid its ₹99 crore credit facility with Kotak Mahindra Bank, comprising a ₹79 crore working capital demand loan and a ₹20 crore cash credit. The repayment was effective from March 2, 2026.

Filing Details

Morepen Laboratories Limited has completed its financial arrangement with Kotak Mahindra Bank by fully repaying a ₹99 crore credit facility. This facility included a ₹79 crore Working Capital Demand Loan and a ₹20 crore Cash Credit limit. The repayment was completed on March 2, 2026.

The company is now seeking the release of assets that were pledged as security for this loan. A No Dues Certificate from Kotak Mahindra Bank is expected as part of this process.

Morepen Labs had secured this facility in December 2024, having informed the exchanges about entering the loan agreement with Kotak Mahindra Bank on December 18, 2024.

Why This Matters

The successful closure of this credit facility suggests proactive financial management and lower immediate debt. It results in a cleaner balance sheet, which could improve the company's credit profile and financial flexibility. The release of charged assets allows them to be used for other strategic purposes or simply reduces outstanding obligations.

However, Morepen Laboratories has also been actively securing new credit lines, such as a ₹50 crore unsecured term loan from Kookmin Bank in November 2025 and another ₹50 crore from Woori Bank in February 2026. This indicates a strategy of actively managing its debt structure, rather than a full deleveraging.

Historical Context

Morepen Laboratories, which operates in APIs, formulations, and medical devices, has faced significant financial challenges historically. In the early 2000s, the company dealt with a severe debt crisis, leading to corporate debt restructuring (CDR) processes due to aggressive expansion that outpaced revenue growth. Past concerns regarding corporate governance have also been noted.

Despite this history, the company has improved its financial standing. As of March 2025, Morepen Labs reported a market capitalization of approximately ₹2,180-2,270 crore, with a low Debt/Equity ratio of 0.07, indicating a substantial improvement from its earlier debt-laden status.

What Changes Now

For shareholders, this means the company's liabilities towards Kotak Mahindra Bank are settled, potentially reducing financial risk. The release of assets can enhance operational agility and reduce the burden of pledges. It also paves the way for improved credit ratings or easier access to future funding based on a stronger balance sheet.

Risks to Watch

While this repayment is positive, Morepen Laboratories' history of debt crises and past governance concerns mean investors should remain vigilant. The company's ongoing need to secure new credit facilities, as seen with the recent Kookmin and Woori Bank loans, underscores the need for sustained operational performance and strong cash flow to manage its overall debt.

Peer Comparison

Morepen Laboratories operates in the small-cap segment, with a market capitalization around ₹2,200-2,270 crore. Its Debt/Equity ratio of 0.07 as of March 2025 is notably low compared to its past, suggesting sound debt management. Larger peers like Sun Pharma or Torrent Pharma operate on a much larger scale with different debt profiles. Companies closer in market cap, such as Dishman Carbogen AMC or Unichem Lab, have different business models and financial exposures that require detailed comparison.

What to Track Next

• Receipt of the 'No Dues Certificate' from Kotak Mahindra Bank.
• The timeline for releasing the previously pledged assets.
• How the company utilizes its newly secured credit facilities from Kookmin Bank and Woori Bank.
• Sustained operational performance and revenue growth to support its overall debt management strategy.